Literature DB >> 21291864

Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy.

Heekyoung Yang1, Su Jin Yoon, Juyoun Jin, Seung Ho Choi, Ho Jun Seol, Jung-Il Lee, Do-Hyun Nam, Hae Yong Yoo.   

Abstract

The most important therapeutic tool in brain metastasis is radiation therapy. However, resistance to radiation is a possible cause of recurrence or treatment failure. Recently, signal pathways about DNA damage checkpoints after irradiation have been noticed. We investigated the radiosensitivity can be enhanced with treatment of Chk1 inhibitor, AZD7762 in lung cancer cell lines and xenograft models of lung cancer brain metastasis. Clonogenic survival assays showed enhancement of radiosensitivity with AZD7762 after irradiation of various doses. AZD7762 increased ATR/ATM-mediated Chk1 phosphorylation and stabilized Cdc25A, suppressed cyclin A expression in lung cancer cell lines. In xenograft models of lung cancer (PC14PE6) brain metastasis, AZD7762 significantly prolonged the median survival time in response to radiation. Depletion of Chk1 using shRNA also showed an enhancement of sensitivity to radiation in PC14PE6 cells. The results of this study support that Chk1 can be a good target for enhancement of radiosensitivity.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21291864     DOI: 10.1016/j.bbrc.2011.01.106

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

Review 1.  Salting the Soil: Targeting the Microenvironment of Brain Metastases.

Authors:  Ethan S Srinivasan; Aaron C Tan; Carey K Anders; Ann Marie Pendergast; Dorothy A Sipkins; David M Ashley; Peter E Fecci; Mustafa Khasraw
Journal:  Mol Cancer Ther       Date:  2021-01-05       Impact factor: 6.261

Review 2.  Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies.

Authors:  Thomas P Matthews; Alan M Jones; Ian Collins
Journal:  Expert Opin Drug Discov       Date:  2013-04-18       Impact factor: 6.098

3.  Targeting lung cancer through inhibition of checkpoint kinases.

Authors:  Randi G Syljuåsen; Grete Hasvold; Sissel Hauge; Åslaug Helland
Journal:  Front Genet       Date:  2015-02-27       Impact factor: 4.599

Review 4.  Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy.

Authors:  Gwenola Manic; Florine Obrist; Antonella Sistigu; Ilio Vitale
Journal:  Mol Cell Oncol       Date:  2015-02-23

5.  CHK1 expression in Gastric Cancer is modulated by p53 and RB1/E2F1: implications in chemo/radiotherapy response.

Authors:  J Bargiela-Iparraguirre; L Prado-Marchal; M Fernandez-Fuente; A Gutierrez-González; J Moreno-Rubio; M Muñoz-Fernandez; M Sereno; R Sanchez-Prieto; R Perona; I Sanchez-Perez
Journal:  Sci Rep       Date:  2016-02-12       Impact factor: 4.379

Review 6.  Targeting the ATR-CHK1 Axis in Cancer Therapy.

Authors:  Stuart Rundle; Alice Bradbury; Yvette Drew; Nicola J Curtin
Journal:  Cancers (Basel)       Date:  2017-04-27       Impact factor: 6.639

7.  Comparative analysis of radiosensitizers for K-RAS mutant rectal cancers.

Authors:  Laura B Kleiman; Angela M Krebs; Stephen Y Kim; Theodore S Hong; Kevin M Haigis
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

8.  Resveratrol enhances ionizing radiation-induced premature senescence in lung cancer cells.

Authors:  Hongmei Luo; Lu Wang; Bradley A Schulte; Aimin Yang; Shengsong Tang; Gavin Y Wang
Journal:  Int J Oncol       Date:  2013-10-17       Impact factor: 5.650

9.  TopBP1 and Claspin contribute to the radioresistance of lung cancer brain metastases.

Authors:  Seung Ho Choi; Heekyoung Yang; Seung Ho Lee; Joo-Hyun Ki; Do-Hyun Nam; Hae Yong Yoo
Journal:  Mol Cancer       Date:  2014-09-12       Impact factor: 27.401

Review 10.  The Current and Future Treatment of Brain Metastases.

Authors:  Douglas A Hardesty; Peter Nakaji
Journal:  Front Surg       Date:  2016-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.